Inhibikase Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.079569 million compared to USD 0.007291 million a year ago. Net loss was USD 4.6 million compared to USD 4.49 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 1.06 a year ago.
For the nine months, revenue was USD 0.2605 million compared to USD 0.059874 million a year ago. Net loss was USD 14.85 million compared to USD 13.78 million a year ago. Basic loss per share from continuing operations was USD 2.93 compared to USD 3.26 a year ago.